Imugene (IMU) investor relations material

Executive summary

• Reported net loss for the half year ended 31 December 2025 was $37.8 million, a 22% improvement year-over-year due to reduced headcount and lower R&D and administrative expenses.

• Cash reserves at period end were $14.1 million, down from $21.9 million at 30 June 2025.

• Major clinical progress in the azer-cel program, with strong response rates in lymphoma trials and positive FDA feedback.

• New collaboration with JW Therapeutics to advance the onCARlytics program, shifting focus to partnered development.

• Institutional placement and share purchase plan raised approximately $25 million to fund operations.

Financial highlights

• Net loss for the period was $37.8 million, down from $48.3 million year-over-year.

• Operating loss improved to $38.2 million from $49.8 million year-over-year.

• R&D expenses decreased to $30.5 million from $31.3 million, with significant reductions across most pipeline programs except OnCARlytics.

• General and administrative expenses fell to $8.5 million from $19.0 million year-over-year.

• Cash and cash equivalents at 31 December 2025 were $14.1 million, down from $33.7 million at 31 December 2024.

• No dividends declared or paid.

Outlook and guidance

• Operating costs for the current financial year are expected to be approximately 50% lower than the prior year.

• Management implemented cost controls and expects further capital raising to support ongoing operations.

• Directors believe the group can meet obligations for at least the next 12 months, but material uncertainty remains regarding going concern due to reliance on future funding.